Olmesartan medoxomil: an angiotensin II-receptor blocker (Q34206338)

31 July 2017

1 reference

title

Olmesartan medoxomil: an angiotensin II-receptor blocker (English)

1 reference

31 July 2017

Julie A Brousil

1

1 reference

31 July 2017

John M Burke

series ordinal

2

1 reference

31 July 2017

publication date

1 April 2003

1 reference

31 July 2017

published in

Clinical Therapeutics

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

1041-1055

1 reference

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Angiotensin II and gene expression in the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Angiotensin II subtype 1 receptor blockers and renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Angiotensin II receptor antagonists and treatment of hypertension and renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Use of angiotensin II receptor blockers in animal models of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980066-8

7 January 2021

10.1016/S0149-2918(03)80066-8

Identifiers

DOI

1 reference

31 July 2017

1 reference